An Intrinsic Calculation For Kiniksa Pharmaceuticals International, Plc (NASDAQ:KNSA) Suggests It's 41% Undervalued
Jefferies Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $45
Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
Kiniksa Pharmaceuticals Price Target Raised to $45.00/Share From $40.00 by Jefferies
Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals International | 10-Q: Q1 2025 Earnings Report
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q1 2025 Earnings Conference
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating
$KNSA Stock Is up 18% Today. Here's What We See in Our Data.
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases
Kiniksa Pharmaceuticals International | 8-K: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
Express News | Kiniksa Pharmaceuticals International PLC: Expects 2025 Arcalyst Net Product Revenue of Between $590 Million and $605 Million
Kiniksa Pharmaceuticals Raises FY2025 Sales Guidance From $560.00M-$580.00M to $590.00M-$605.00M Vs $698.99M Est
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q1 Revenue $137.8M, Vs. FactSet Est of $131.9M
Express News | Kiniksa Pharmaceuticals International PLC: Kpl-387 Phase 2/3 Clinical Trial in Recurrent Pericarditis on Track to Initiate in Mid-2025
Press Release: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
Express News | Kiniksa Pharmaceuticals Q1 EPS USD 0.12
Express News | Kiniksa Pharmaceuticals Q1 Operating Expenses USD 124.513 Million
Express News | Kiniksa Pharmaceuticals Q1 Product Revenue USD 137.785 Million